
New study confirms link between cancer patients’ quality of life and survival
1 Apr 2025

New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
17 Sep 2024

Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023

New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023

EORTC’s presence at ESMO 2023
17 Oct 2023

FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
30 Jan 2023

EORTC, CTI, and IRROG collaboration opens new opportunities in Ireland
12 Dec 2022

Results of two EORTC studies have been published in NEJM and the Lancet Oncology
21 Sep 2022